Support structured symptom monitoring

The manuals converge on the need for repeated, structured monitoring rather than one-off impressions. Across the extracts, symptom tracking is framed as part of a protocol, whether through repeated anxiety assessments and daily diaries of anxiety, pain, and medication use, or through serial safety observations that capture change over time. They also share an emphasis on using monitoring to support interpretation of participant responses within the wider study context. The sources differ in what they monitor and why. The LDA-1 material centres on anxiety, pain, and medication use in relation to psychotherapy sessions and a broader research schedule. The 5-MeO-DMT study focuses on understanding baseline moderate anxiety and or depression symptoms in a non-diagnosed, non-treated sample, with attention to distinguishing transient drug effects from underlying psychiatric status. The ibogaine study is more explicitly safety oriented, using standardised measures for cardiac, neurologic, and psychomimetic effects, including QTc, SARA, and DOS.